The market size of the Global Biospecimen Contract Research Services Market is predicted to grow with a considerable CAGR of 9.3% during the forecast period. Increased investment in pharmaceutical R&D, an increase in the number of clinical trials, and the high cost of in-house drug development are driving growth in the Biospecimen Contract Research Services Market (encouraging pharma-biotech companies to outsource). Growth in the drugs and biologics market despite the COVID-19 pandemic, rising demand for specialized testing services among end-users, and the need for novel clinical trial designs for complex cell and gene therapies are all expected to provide a wide range of growth opportunities for market participants. Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in developing new drugs and devices. In the pharmaceutical industry, R&D is essential, and pharmaceutical firms invest in research and development to bring high-quality, innovative products to market. The increased investment in biologics and biosimilars by biopharmaceutical companies is attributed to an increase in the number of approved products globally. Biologics like proteins, peptides, and monoclonal antibodies currently account for more than half of all drug candidates in the discovery stage.
The Biospecimen Contract Research Services market is segmented into the biospecimen types and therapeutics areas. Based on the type of biospecimen types, the market is segmented into oncological and non-oncological studies. The oncological studies are further segmented into FFPE Tissue, Frozen Tissue, Plasma / Serum and Other Biospecimens. The non-oncological studies are further segmented into Blood Products, Human Tissue and Other Biospecimens. The therapeutics area segment includes Oncological Disorders, Neurological Disorders, Cardiovascular Disorders and Other Therapeutic Areas.
Based on Biospecimen Type, the oncological studies segment is accounted as a significant contributor in the Biospecimen Contract Research Services market.
The oncological studies segment is accounted as a significant contributor in the Biospecimen Contract Research Services market. The demand for biospecimens in cancer research has increased, but there is little data on biospecimen usage trends. These data are required to forecast future demand. This was due to larger cohort sizes for both frozen and FFPE tissues. For decades, Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens have been a mainstay of research and therapeutic applications. FFPE is a type of biopsy specimen preservation and preparation that aids in the examination, experimental research, and diagnostic/drug development. To preserve the proteins and vital structures within the tissue, a tissue sample is first fixed in formaldehyde, also known as formalin. It is then embedded in a paraffin wax block, making it easier to cut slices of the required sizes for examination on a microscopic slide.
The oncological disorders segment witnessed growth at a rapid rate.
Oncology, or the study of cancer and tumours, has made significant advancements in the prevention, treatment, and prognosis of many childhood cancers. Despite this progress, cancer remains the leading cause of death in children. Childhood cancer differs from adult cancers in terms of development, treatment, response to therapy, therapy tolerance, and prognosis. In most cases, childhood cancer responds better to treatment, the child can tolerate more aggressive treatment, and the forecast is better.
The North America Biospecimen Contract Research Services market holds a significant revenue share in the region.
North America dominated the global biospecimen contract research services market. North America's dominance in this market is primarily due to the market's rapid growth, pharmaceutical and biopharmaceutical companies' increased focus on outsourcing, and an increase in the number of clinical trial activities in the region. The rising popularity of precision/personalized medicine and genetic testing has been a major driving force in the region's market. Biobanks have long been essential in biomedical research. Over the last few decades, there have been several advancements in the platforms and tools used in genetic studies. This has resulted in increased clinical lab demand for biospecimens to develop assays for genetic testing in this region.
The key players in the Biospecimen Contract Research Services market have shifted their focus towards bio-based components for product manufacturing and are initiating effective strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their market footprint across the globe. Some of the major key players in the Biospecimen Contract Research Services market are BioChain Institute, BioIVT, Boca Biolistics, Creative Bioarray, Cureline, Discovery Life Sciences, Infinity BiologiX, Precision for Medicine, Inc., PrecisionMed, Inc., Medicover, National BioService, ICON plc, The MT Group, Eolas Biosciences Co. Ltd, Indivumed GmbH, Ardent Clinical Research Services, Capital Biosciences, Inc., GR BioResearch, REPROCELL, Trans-Hit Bio (Azenta US, Inc.) and iSpecimen.